Literature DB >> 9216704

Outcome of patients with lung cancer detected by mass screening versus presentation with symptoms.

H Satoh1, H Ishikawa, Y T Yamashita, T Naito, H Takahashi, H Kamma, Y Saito, M Ohtsuka, S Hasegawa.   

Abstract

Lung cancers in the early stages are frequently detected via mass screening in Japan. The aim of this study is to evaluate the outcome of patients with lung cancer detected via mass screening and to compare them to those in whom the malignancy was detected by symptoms. A total of 774 untreated patients with lung cancer who were admitted to Department of Respiratory Medicine, Tsukuba University Hospital over a 20 year period up to 1995, were analyzed with reference to their reasons for detection of the cancer. In the mass screened group(116 patients), 50.0% of lung cancer was detected at stage I of TNM classification, while only 8.2% of patients with symptoms(561 patients) had stage I lung cancer (p = 0.0001). As lung cancers detected via mass screening were more often at operable stage (stage I, II or IIIA) (p = 0.0001), surgical treatment was chosen more frequently in the mass screened group(p = 0.0001). The outcome of patients with lung cancer detected via mass screening was more favorable than that of the patients detected by their symptoms (p = 0.0002). The early detection of lung cancer via mass screening contributes to improvement of the outcome.

Entities:  

Mesh:

Year:  1997        PMID: 9216704

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  2 in total

1.  Volume doubling time of lung cancers detected in a chest radiograph mass screening program: Comparison with CT screening.

Authors:  Maki Kanashiki; Takuji Tomizawa; Iwao Yamaguchi; Koichi Kurishima; Nobuyuki Hizawa; Hiroichi Ishikawa; Katsunori Kagohashi; Hiroaki Satoh
Journal:  Oncol Lett       Date:  2012-06-28       Impact factor: 2.967

2.  Use of screening tests, diagnosis wait times, and wait-related satisfaction in breast and prostate cancer.

Authors:  M Mathews; D Ryan; V Gadag; R West
Journal:  Curr Oncol       Date:  2014-06       Impact factor: 3.677

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.